NORISODRINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Norisodrine, and what generic alternatives are available?
Norisodrine is a drug marketed by Abbvie and Abbott and is included in two NDAs.
The generic ingredient in NORISODRINE is isoproterenol hydrochloride. There are seventeen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the isoproterenol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norisodrine
A generic version of NORISODRINE was approved as isoproterenol hydrochloride by NEXUS on August 2nd, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NORISODRINE?
- What are the global sales for NORISODRINE?
- What is Average Wholesale Price for NORISODRINE?
Summary for NORISODRINE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 62 |
| Patent Applications: | 3,875 |
| DailyMed Link: | NORISODRINE at DailyMed |
US Patents and Regulatory Information for NORISODRINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | NORISODRINE | isoproterenol sulfate | POWDER;INHALATION | 006905-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | NORISODRINE | isoproterenol sulfate | POWDER;INHALATION | 006905-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbott | NORISODRINE AEROTROL | isoproterenol hydrochloride | DISC;INHALATION | 016814-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
